{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:37Z","timestamp":1792790497617,"version":"4.5.0"},"reference-count":21,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Alexion","id":[{"id":"https:\/\/ror.org\/00vh0j257","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Hypophosphatasia (HPP) is a rare recessive or dominant autosomal disease caused by loss-of-function variants in the ALPL gene, which encodes tissue-nonspecific alkaline phosphatase (TNSALP). Molecules involved in the pathogenesis of HPP are alkaline phosphatase (ALP), inorganic pyrophosphate (PPi; an inhibitor of bone mineralization), pyridoxal-5\u2019-phosphate (PLP; responsible for the neurological complications) and phosphoethanolamine. Asfotase alfa is a recombinant, bone-targeted, human TNSALP approved to treat patients with HPP. Its clinical effectiveness has been demonstrated in real-world settings across international HPP registries. However, evidence from routine clinical practice in Spain is lacking. Here, we report three Spanish cases of HPP treated successfully with asfotase alfa: a girl diagnosed at 3 months; a woman diagnosed at age 47 years; and a 27-year-old woman with paediatric- onset symptoms. In all cases, asfotase alfa treatment was associated with an increase in serum ALP, marked reductions in plasma PPi and PLP, and marked improvements in symptoms and physical performance. Our series of HPP cases confirms the beneficial effects of asfotase alfa on biochemical and clinical outcomes, consistent with evidence from randomized clinical trials.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-biochemical-and-clinical-changes-during-enzymatic-replacement-therapy-in-hypophosphatasia-three-real-world-cases-in-spain<\/jats:p>","DOI":"10.7573\/dic.2026-5-14","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:30:23Z","timestamp":1790847023000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Biochemical and clinical changes during enzymatic replacement therapy in hypophosphatasia: three real-world cases in Spain"],"prefix":"10.7573","author":[{"given":"Mercedes","family":"Marb\u00e1n Calz\u00f3n","sequence":"first","affiliation":[{"name":"Hospital General Mancha Centro, Alc\u00e1zar de San Juan, Ciudad Real, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Pilar","family":"Aguado Ac\u00edn","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01s1q0w69","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario La Paz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0968-3234","authenticated-orcid":false,"given":"Juan Luis","family":"Carrillo-Linares","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xxs2z38","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Cl\u00ednico Universitario Virgen de la Victoria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gonz\u00e1lez Jimeno","sequence":"additional","affiliation":[{"name":"Hospital General Mancha Centro, Alc\u00e1zar de San Juan, Ciudad Real, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-0352","authenticated-orcid":false,"given":"Jos\u00e9","family":"Rioja Villodres","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05n3asa33","id-type":"ROR","asserted-by":"publisher"}],"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8484-3475","authenticated-orcid":false,"given":"Carolina","family":"Tornero Mar\u00edn","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01s1q0w69","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario La Paz"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tWhyte MP. Hypophosphatasia \u2212 aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016;12:233\u2212246. https:\/\/doi.org\/10.1038\/nrendo.2016.14","DOI":"10.1038\/nrendo.2016.14"},{"key":"ref1","unstructured":"2.\tUnited States Food & Drug Administration. STRENSIQ\u00ae (asfotase alfa) injection. Prescribing Information. https:\/\/ www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125513s033lbl.pdf. Accessed May 27, 2026."},{"key":"ref2","unstructured":"3.\tEuropean Medicines Agency. Strensiq (asfotase alfa) solution for injection. Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/strensiq-epar-product-information_en.pdf. Accessed May 27, 2026."},{"key":"ref3","unstructured":"4.\tPharmaceuticals and Medical Devices Agency. Strensiq (asfotase alfa) subcutaneous injection. Report on the Deliberation Results. https:\/\/www.pmda.go.jp\/files\/000213563.pdf. Accessed May 27, 2026."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tKishnani PS, Rockman-Greenberg C, Rauch F, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019;121:149\u2212162. https:\/\/doi.org\/10.1016\/j.bone.2018.12.011","DOI":"10.1016\/j.bone.2018.12.011"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tWhyte MP, Simmons JH, Moseley S, et al. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol. 2019;7:93\u2212105. https:\/\/doi.org\/10.1016\/S2213-8587(18)30307-3","DOI":"10.1016\/S2213-8587(18)30307-3"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tHofmann CE, Harmatz P, Vockley J, et al. Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study. J Clin Endocrinol Metab. 2019;104:2735\u22122747. https:\/\/doi.org\/10.1210\/ jc.2018-02335","DOI":"10.1210\/jc.2018-02335"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tBowden SA, Adler BH. Reappearance of hypomineralized bone after discontinuation of asfotase alfa treatment for severe childhood hypophosphatasia. Osteoporos Int. 2018;29:2155\u20132156. https:\/\/doi.org\/10.1007\/s00198-018-4613-7","DOI":"10.1007\/s00198-018-4613-7"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tS\u00e1nchez-T\u00e9var AM, Garc\u00eda-Fern\u00e1ndez M, Murcia-Casas B, et al. Plasma inorganic pyrophosphate and alkaline phosphatase in patients with pseudoxanthoma elasticum. Ann Transl Med. 2019;7:798. https:\/\/doi.org\/10.21037\/ atm.2019.12.73","DOI":"10.21037\/atm.2019.12.73"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tYang J, Bauer BA, Wahner-Roedler DL, Chon TY, Xiao L. The modified WHO analgesic ladder: is it appropriate for chronic non-cancer pain? J Pain Res. 2020;13:411\u2212417. https:\/\/doi.org\/10.2147\/JPR.S244173","DOI":"10.2147\/JPR.S244173"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tNarv\u00e1ez-Fern\u00e1ndez E, Lluch-Bernal M, Fiandor A, et al. Successful desensitization to asfotase alfa in hypophosphatasia: a case report and IgE-mediated mechanism confirmation. Allergo J Int. 2024;33:94\u201396. https:\/\/doi.org\/10.1007\/s40629-023-00279-0","DOI":"10.1007\/s40629-023-00279-0"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tNg E, Ashkar C, Seeman E, et al. A low serum alkaline phosphatase may signal hypophosphatasia in osteoporosis clinic patients. Osteoporos Int. 2023;34:327\u2013337. https:\/\/doi.org\/10.1007\/s00198-022-06597-3","DOI":"10.1007\/s00198-022-06597-3"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tGarc\u00eda-Fontana C, Villa-Su\u00e1rez JM, And\u00fajar-Vera F, et al. Epidemiological, clinical and genetic study of hypophosphatasia in a Spanish population: identification of two novel mutations in the Alpl gene. Sci Rep. 2019;9:9569. https:\/\/doi.org\/10.1038\/S41598-019-46004-2","DOI":"10.1038\/s41598-019-46004-2"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tTornero C, Navarro-Comp\u00e1n V, Tenorio JA, et al. Can we identify individuals with an ALPL variant in adults with persistent hypophosphatasaemia? Orphanet J Rare Dis. 2020;15:51. https:\/\/doi.org\/10.1186\/s13023-020-1315-y","DOI":"10.1186\/s13023-020-1315-y"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tWhyte MP. Hypophosphatasia: an overview for 2017. Bone. 2017;102:15\u201325. https:\/\/doi.org\/10.1016\/J.BONE.2017.02.011","DOI":"10.1016\/j.bone.2017.02.011"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tZhang Z, Nam HK, Crouch S, Hatch NE. Tissue nonspecific alkaline phosphatase function in bone and muscle progenitor cells: control of mitochondrial respiration and ATP production. Int J Mol Sci. 2021;22:1140. https:\/\/doi.org\/ 10.3390\/IJMS22031140","DOI":"10.3390\/ijms22031140"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tDahir KM, Seefried L, Kishnani PS, et al. Clinical profiles of treated and untreated adults with hypophosphatasia in the Global HPP Registry. Orphanet J Rare Dis. 2022;17:277. https:\/\/doi.org\/10.1186\/S13023-022-02393-8","DOI":"10.1186\/s13023-022-02393-8"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tShajani-Yi Z, Ayala-Lopez N, Black M, Dahir KM. Urine phosphoethanolamine is a specific biomarker for hypophosphatasia in adults. Bone. 2022;163:116504. https:\/\/doi.org\/10.1016\/J.BONE.2022.116504","DOI":"10.1016\/j.bone.2022.116504"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tB\u00e4ck M, Aranyi T, Cancela ML, et al. Endogenous calcification inhibitors in the prevention of vascular calcification: a consensus statement from the COST Action EuroSoftCalcNet. Front Cardiovasc Med. 2019;5:196. https:\/\/doi.org\/ 10.3389\/fcvm.2018.00196","DOI":"10.3389\/fcvm.2018.00196"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tAndrilli LHS, Sebinelli HG, Favarin BZ, et al. NPP1 and TNAP hydrolyze ATP synergistically during biomineralization. Purinergic Signal. 2023;19:353\u2212366. https:\/\/doi.org\/10.1007\/S11302-022-09882-2","DOI":"10.1007\/s11302-022-09882-2"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tNitschke Y, Rutsch F. Inherited arterial calcification syndromes: etiologies and treatment concepts. Curr Osteoporos Rep. 2017;15(4):255\u2212270. https:\/\/doi.org\/10.1007\/s11914-017-0370-3","DOI":"10.1007\/s11914-017-0370-3"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/10\/dic.2026-5-14.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:30:38Z","timestamp":1790847038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/biochemical-and-clinical-changes-during-enzymatic-replacement-therapy-in-hypophosphatasia-three-real-world-cases-in-spain"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-5-14","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"dic.2026-5-14"}}